NanoViricides starts Phase II DRC trial of oral NV-387 gummies in Bundibugyo Ebola patients

Bitget2026/09/28 12:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NanoViricides began enrolling and dosing patients in a Phase II trial of NV-387 oral gummies for Ebola in the Democratic Republic of Congo.
No results have been presented; the study is designed to generate safety, tolerability, and effectiveness data in a later randomized phase.
The initial dose run-in aims to set a tolerable dosing approach for sicker patients before moving into the efficacy evaluation.
The program targets Bundibugyo ebolavirus, positioning NV-387 as a potential oral alternative to infusion-based treatments under evaluation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609280845ACCESSWRNAPR_____1227696) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NanoViricides starts Phase II DRC trial of oral NV-387 gummies in Bundibugyo Ebola patients

You may also like

Crypto prices